Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can family therapy prevent psychosis in At-Risk youth?

NCT ID NCT04338152

Disease control Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a family-focused therapy for 220 youth aged 13-25 who show early signs of psychosis risk. The therapy aims to reduce symptoms and prevent the development of full psychosis over 18 months. Participants receive either the family therapy or a comparison treatment, with regular check-ins to track progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Participants must be able to understand and sign an informed consent (or assent for minors) document in English; 2. Youth has at least one parent or legal guardian who participants sees often enough (minimum 4 hours/week) that family intervention is sensible, who is English-speaking, and who consents to study participation and treatment sessions; and 3. Youth currently meets criteria for clinical high-risk (CHR) for psychosis, with attenuated positive symptoms that have begun or worsened in the past 12 months, genetic risk and deterioration, or brief intermittent psychotic symptoms. Eligible participants may meet DSM-5 criteria for any non-psychotic disorder (e.g. major depression, anxiety disorders, ADHD), as long as the disorder does not clearly account for the presence of psychosis risk symptoms. Exclusion Criteria 1. Current or lifetime Axis 1 psychotic disorder by DSM-5 criteria 2. Impaired intellectual functioning (IQ\<70) 3. Unwilling or unable to taper individual therapy to monthly by start of treatment 4. Past or current history of a clinically significant medical or central nervous system disorder that may contribute to CHR symptoms or confound assessment 5. Severe substance or alcohol use disorder within the past 6 months, and/or substance use (including cannabis) is causally related to recent onset of CHR symptoms so as to confound prodromal diagnostic determination. If either an exclusionary medical condition or an incidental medical condition is suspected, the participant will be advised to consult with their physician or will be referred to a specialist. Eligibility for the trial will be reconsidered if the medical condition has been treated to remission and the subject still meets CHR criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Prodromal Symptoms Psychotic Disorders schizotypal personality disorder psychotic disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAMILY Prodromal schizophrenia Prodromal symptoms Psychosis Psychotic disorders

Contacts and locations

Locations

  • Harvard University/Beth Israel Deconess Medical Center

    Boston, Massachusetts, 02215, United States

  • University of Calgary

    Calgary, Alberta, Canada

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of California, San Diego

    San Diego, California, 92093, United States

  • University of California, San Francisco School of Medicine

    San Francisco, California, 94121, United States

  • Yale University

    New Haven, Connecticut, 06519, United States

  • Zucker Hillside Hospital

    New York, New York, 11004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.